CLINICAL QUESTION: Is initial empiric antibiotic coverage important in patients with febrile neutropenia? How should the therapeutic strategy be defined?
BACKGROUND: Febrile neutropenia is defined as a single oral temperature greater than 38.3°C or a sustained temperature greater than 38°C for more than one hour in a patient with an absolute neutrophil count (ANC) of less than 500 cells/mL, or an ANC expected to decrease to less than 500 cells/mL within 48 hours. Prompt initiation of empiric broad-spectrum antibiotics has been shown to significantly reduce mortality. However, not all patients have the same risk of complications, and advances in supportive care have made outpatient management feasible for selected low-risk patients. Accurate risk stratification and appropriate antimicrobial selection are therefore critical.
STUDY DESIGN: Evidence-based clinical practice review
SETTING: Tertiary-care hospitals
SYNOPSIS: The cornerstone of management is the “one-hour rule”—administering empiric broad-spectrum intravenous antibiotics within 60 minutes of presentation. The treatment strategy is based on risk stratification using the MASCC Risk Index for Febrile Neutropenia. Low-risk patients (score at least 21) may be managed as outpatients with oral antibiotics such as ciprofloxacin and amoxicillin-clavulanate. High-risk patients require hospital admission and broad-spectrum intravenous therapy, such as cefepime or piperacillin-tazobactam, to cover gram-negative pathogens, including Pseudomonas. Vancomycin should be added only in the presence of hemodynamic instability, skin or catheter infection, suspected methicillin-resistant Staphylococcus aureus pneumonia, severe mucositis, or blood cultures showing gram-positive cocci. In clinically stable patients with persistent fever after three to four days and no identified source, escalation of therapy is not necessary; fever alone does not justify modification of antimicrobial treatment. In neutropenic patients, untreated gram-negative bacteremia carries a mortality rate of up to 70%. With empiric antibiotic therapy, mortality is significantly reduced to a range of 4% to 20%.
BOTTOM LINE: Optimal management of febrile neutropenia requires urgent assessment and prompt initiation of empiric antibiotics targeting gram-negative pathogens, using the MASCC score and hemodynamic stability to safely determine whether hospital admission is required or outpatient management is appropriate.
CITATION: Zimmer AJ, Freifeld AG. Optimal management of neutropenic fever in patients with cancer. J Oncol Pract. 2019;15(1):19-24. doi: 10.1200/JOP.18.00269.
Dr. Vernengo is a clinical medicine PGY 3 in the department of clinical medicine at Hospital Aleman and an instructor of internal medicine at the University of Salvador, both in Buenos Aires, Argentina.